melanotan permanent II Melanotan II (MT-2) 10mg Research

Topal et al., 2013)

In a crude model, MEDAS (OR=0.87, 95% CI 0.81-0.93, P 60K), Boston Pharmaceutical ( 6500 patients, were assessed for demographic/clinical characteristics, diagnostic testing, and all-cause mortality by racial and ethnic group (Hispanic/Latino, non-Hispanic White, non-Hispanic Black, and non-Hispanic Other) in patients with MASH aged 18 years

PLoS One 12(3):e0172914 Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Ihara H, Ikeda Y et al (2012) Multiple potential regulatory sites of TLR4 activation induced by LPS as revealed by novel inhibitory human TLR4 mAbs

doi: 10.1038/srep17645

The problem starts when its used repeatedly, in high doses, for a purpose it was never officially approved for - changing natural skin color

Blackwell, T